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Objectives – The aim of the present investigation was to form matrix patches with ethyl cellulose (EC) as 
the base polymer, polyvinyl pyrrolidone (PVP) as the copolymer, plasticizer with dibutyl phthalate (DBP) 
or acetyl tributyl citrate (ATBC) and the drug glipizide (gz) by the solvent casting method. Physicochemical 
properties of the patches and in vitro drug release were determined in a modified Keshary–chien diffusion 
cell to optimize the patch formulations with the help of experimental data and figures for further studies. 
Techniques – EC and PVP of different proportions with different weight percentages of either DBP or ATBC 
and a fixed amount of glipizide were taken for matrix patch formations. The dried patches were used for 
measuring their drug contents as well as their thicknesses, tensile strengths, moisture contents and water 
absorption amounts in percentage. In vitro release amounts at different intervals were measured by UV-
spectrophotometer. Results – Drug contents varied from 96 – 99%. Thickness and tensile strength varied due 
to weight variation of the ingredients in the matrix patches. Moisture content and water absorption in wt % 
were greater for the patches containing higher amount of PVP due to its hydrophilic nature. Variations in drug 
release were observed among various formulations. It was found that all of the releases followed diffusion 
controlled zero order kinetics. Two DBP patches yielded better and more adequate release. Conclusions – 
The two formulations with DBP were the preferred choice for making matrix patches for further studies. 
Uniterms: Glipizide/physicochemical properties. Glipizide/in-vitro release. Ethyl cellulose. Polyvinyl 
pyrrolidone. Plasticizer.
O objetivo da presente pesquisa foi formar matrizes para bandagens de liberação transdérmica com 
etilcelulose (EC) como polímero base, polivinilpirrolidona (PVP), como copolímero, plastificante com 
ftalato de dibutila (DBP) ou citrato de tributilacetila (ATBC) e o fármaco glipizida (gz) pelo método de 
evaporação do solvente (moldagem com solvente). As propriedades físico-químicas das bandagens e 
a liberação do fármaco in vitro na célula de difusão de Keshary-chien modificada foram determinadas 
para aperfeiçoar as formulações das bandagens com o auxílio de dados experimentais e figuras para 
estudos posteriores. EC e PVP em diferentes proporções com porcentagens diferentes de massa tanto de 
DBP quanto de ATBC e quantidade fixa de glipizida foram utilizadas como matrizes para a formação de 
bandagens de liberação transdérmica. As bandagens secas foram empregadas para medir seus conteúdos 
em fármaco e, também, a sua espessura, resistência à tensão, conteúdos de umidade e porcentagem de 
absorção de água. As quantidades liberadas in vitro em diferentes intervalos de tempo foram medidas por 
espectrofotômetro de UV. Os conteúdos de fármaco variaram de 96 a 99%. A espessura e a resistência à 
ruptura variaram devido à variação de massa dos componentes da matriz das bandagens. O conteúdo de 
umidade e a água absorvida, em porcentagem de massa, foram maiores para as bandagens que continham 
grandes quantidades de PVP devido à sua natureza hidrofílica. As variações na liberação de fármaco foram 
observadas entre as várias formulações. Todas as liberações seguiram a cinética de difusão controlada de 
ordem zero. Duas bandagens DBP resultaram em melhor e mais adequada liberação. As duas formulações 
com DBP foram escolhidas para a preparação de matriz de bandagens para estudos posteriores.
Unitermos: Glipizida/propriedades físico-químicas. Glipizida/liberação in vitro. Etil celulose. Polivinil 
pirrolidona. Plastificante.
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INTRODUCTION
Diabetes mellitus is a major and growing health 
problem worldwide and an important cause of prolonged 
ill health and early death (Arunachalam, Gunasekaran, 
2002). It is a chronic metabolic disorder characterized 
by a high blood glucose concentration (hyperglycemia) 
caused by insulin deficiency and it is often combined with 
insulin resistance (Davis, Granner, 1996; Nolte, Karam, 
2003). Glipizide is an oral blood-glucose-lowering drug 
of the sulfonylurea class. Glipizide has been in extensive 
use to treat NIDDM and acts by increasing the release of 
endogenous insulin as well as its peripheral effectiveness. 
It has been associated with severe and sometimes fatal 
hypoglycemia and gastric disturbances such as nausea, 
vomiting, heartburn, anorexia and increased appetite 
after oral therapy. Since these drugs are usually intended 
to be taken for a long period, patient compliance is also 
very important. Transdermal delivery has many advan-
tages over the oral route of drug administration; it avoids 
hepatic first pass metabolism, termination of further 
administration, long term duration, potentially decreases 
side effects and improves patient compliance. Therefore, 
an attempt was made to formulate transdermal glipizide 
patches (Bennette et al., 2005; Mutalik, Udupa, 2002; 
Mutalik, Udupa, 2003; Mutalik, Udupa, 2004; Mutalik, 
Udupa, 2005; Mutalik, Udupa, 2006; Mutalik et al., 
2006) which can reduce frequency of dosing and some 
of the complications of higher dose oral therapy. There 
is also the feasibility of transdermal delivery of glipi-
zide to consider. Glipizide (molecular weight 445.5 Da) 
shows a favourable partition coefficient (log octanol/
buffer: 0.28 ± 0.12) and negligible skin degradation. The 
present research work was carried out with two different 
plasticizers of two different weight proportions using EC 
as a main polymer and PVP as a co-polymer. Different 
physicochemical properties of these matrix patches were 
studied. An in vitro model for the release of glipizide 
from matrix patches was carried out to study the effect 
of copolymer and plasticizers.
MATERIALS AND METHODS
Glipizide (BP grade) was kindly donated by Sun 
Pharma, Dadra, India. Ethyl cellulose (N 22) was gifted 
from Pharma- Signet Chemical Corporation, Mumbai, 
India. Polyvinyl pyrrolidone (K-30) was obtained from 
SRL Pvt. Ltd., Mumbai, India. DBP was purchased from 
Qualigens Fine Chemicals, India. ATBC was gifted by 
Morflex, USA. All other chemicals used in the study were 
of analytical grade.
Analytical method
A total of 100 mg of glipizide was accurately wei-
ghed, placed in a l00 mL volumetric flask and dissolved 
in methanol. 10 mL of this solution was taken in a 100 mL 
volumetric flask. In order to generate a calibration curve, 
2 to 30 μg/mL of primary standard were prepared and 
the calibration curve was obtained by measuring their 
absorbance at predetermined UV- VIS spectrophotometer 
at 275 nm. The concentration of glipizide was calculated 
using the linear regression equation of the calibration 
curve (Absorbance = 0.0236 × concentration + 0.0149, 
r2 = 0.9959). When a standard drug solution was assayed 
repeatedly (n = 6), mean standard error (accuracy) and RSD 
(precision) were found to be 0.3% and 0.5%, respectively.
Preparation of transdermal patches
For preparation of the patches, 300 mg of EC was 
dissolved in 5 mL chloroform followed by the addition of 
50 - 200 mg of PVP by stirring the total mass with a mag-
netic stirrer. Subsequently, 15 mg of gz and the plasticizer, 
either DBP or ATBC (each 20-30% of the total weight of 
EC and PVP), were added with stirred mass. The total 
mass was then slowly poured into the center of SS rings 
having a backing layer of aluminum foil. The total mass 
was dried at room temperature for 24 h (Kulkarni et al., 
2002; Munden et al., 1964). The dried patches were taken 
in a plastic seal bag and stored in desiccators. The patch 
characteristics are presented in Table I.
Drug content
A small circular known area from each patch was 
cut, weighed accurately, dissolved in 2 mL casting solvent, 
and the volume diluted with a known amount of distilled 
water to measure the total amount of drug content present 
TABLE I - Patch combination
Patch code EC
(mg)
PVP
(mg)
Glipizide
(mg)
DBP
(%)
ATBC
(%)
F1
F2
F3
F4
F5
F6
F7
F8
F9
F10
300
300
300
300
300
300
300
300
300
300
200
150
200
150  
200
150
100
50
200
150
15
15
15
15
15
15
15
15
15
15
20
20
30
30
30
30
-
-
  
20
20
30
30
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in the area by UV-VIS spectrophotometer at 275 nm. This 
yields the actual amount of drug present. The theoretical 
amount is calculated using the equation: 
 [(15 mg of drug × small cut piece area)/total area 
of the patch].
The percentage ratio between actual amount and the-
oretical amount gives the drug content in percentage. Six 
similar readings from six patches of the same composition 
were determined and an average with standard deviation 
(SD) is shown in Table II.
Determination of patch thickness
The thickness of a patch was measured by a digital 
micrometer (Mitutoyo, Japan). Six samples of each formu-
lation were taken and measurements were made. Average 
thickness is shown in Table II.
Determination of tensile strength
The tensile strength of the patch was evaluated using 
an Instron 4204, UK tensilometer with a mounted load of 
50 KN. Six samples of each formulation were tested with 
an extension speed of 5 mm/m [American Society for 
Testing Materials(ASTM); method D 882- 75D]. The test 
was carried out at 25±2 °C and 56%±2% RH. The tensile 
strength was calculated from the equation, 
t = L
max
/A
i
  (1)
Where τ is the tensile strength; L
max 
is the
 
maximum 
load and A
i
 is the initial cross sectional area of the sample. 
An average value is shown in Table II.
Moisture content
Three patches of the same composition were wei-
ghed individually and kept in a dessicator containing fused 
calcium chloride at 40°C for 24 h (Mukherjee et al. 2005a). 
The patches were then reweighed until a constant weight 
was obtained. The moisture content of a patch was calcu-
lated as a percentage based on the difference between the 
initial and constant final weight of the patch. An average 
is shown in Table II.
Water absorption studies
To determine the water absorption capacity of the 
patches, three weighed patches of the same composition 
were kept at room temperature for 24 h and exposed to 
two relative humidities of 75% (a saturated solution of 
sodium chloride) and 93% (a saturated solution of am-
monium hydrogen phosphate) in different desiccators at 
room temperature (Mukherjee et al. 2005b). The water 
absorption capacity of the patches was determined as the 
percentage increase in the weight of the patch divided by 
its initial weight. The weights were periodically recorded 
until a constant weight was obtained. An average was 
recorded (Table II).
In vitro release studies
The In vitro release studies were carried out in a mo-
dified Keshary-chien diffusion cell. A piece of matrix patch 
(circular, 2.5 cm diameter) was mounted carefully on the 
donor compartment. The donor compartment was empty 
and the backing membrane side of the matrix patch was 
open to the atmosphere while the receptor compartment 
was filled with freshly prepared phosphate buffer saline 
pH 7.4. Outside the receptor compartment, water from a 
constant temperature bath flowed continuously through the 
jacket at 37±0.5°c. The receptor liquid was slowly stirred 
by magnetic stirrer at 40-50 rpm. The temperature in the 
release/permeation area was maintained at 37±0.5°C. The 
TABLE II - Patch characteristics
 
Patch code %Glipizide content
(Avg ± SD)
Patch
Tensile strength
(N/mm2)
Patch thickness 
(μm)
Moisture 
content 
(Wt %)
Water absorption
(Wt %)
75% RH            93% RH
F5
F6
F7
F8
F9
F10
97 ± 6.52
98 ± 5.52
99 ± 5.56
99 ± 4.52
96.65± 6.50
96 ± 6.10
11.489
13.675
7.705
7.383
11.800
14.200
182
172
135
116
190
187
1.20
1.13
1.07
1.00
1.21
1.14
3.40                 3.80
2.42                 2.98
2.38                 2.72
1.61                 2.04
3.60                 4.00
2.54                 2.64
Notations: Avg: Average; SD: Standard deviation; 75% RH and 93% RH: 75% relative humidity and 93% relative humidity, 
respectively.
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volume of the receptor liquid (53 mL) was such that the 
piece of the matrix patch (drug side) just touches the re-
ceptor liquid surface horizontally for molecular diffusion. 
Samples (2 mL) were withdrawn at 1 hr intervals up to 8 h 
and replaced immediately with the same volume of saline 
solution. Samples were analyzed by UV at 275 nm after 
suitable dilution. Release parameters are given in Table III.
Data and statistical analysis
The steady state release rate (µg/cm2/h) was calcu-
lated from the slope of the linear plot of the cumulative 
amount released per unit area (µg/cm2) as a function of 
time (t, h).
Data are presented as mean ± standard deviation 
(SD). Statistical comparisons were made using Student’s 
t-test at a significance level of p<0.05 using MS-excel 
software. 
RESULTS AND DISCUSSION
DBP and ATBC were used as plasticizers to prepa-
re the patches. The tensile strength of only the patches 
containing 30% DBP or 30% ATBC as plasticizer was 
measured. Other patches containing 20% of plasticizer 
were discarded as they are brittle in nature (as in the case 
of F1, F2, F3 and F4). From Table II, it is clear that patches 
containing ATBC have greater tensile strength compared 
to those with DBP. Plasticizer embeds between the chains 
of polymers, spacing them apart and making the polyme-
ric patch more flexible. Therefore, the presence of higher 
molecular weight ATBC increases the tensile strength of 
the polymeric patches. Thus, the tensile strength of patch 
F9 was greater than that of F5 while the tensile strength 
of patch F10 was greater than that of F6. Moreover, a 
PVP increase in DBP patches increases the tensile streng-
th (thus tensile strength of F6 > tensile strength of F7 > 
tensile strength of F8). Addition of higher amounts of 
PVP reduces the matrix tensile strength. Thus, the tensile 
strength of F5 was less than that of F6 (Mosquera, 1997). 
Thickness of the patches containing ATBC was slightly 
greater than that of DBP patches. However, the moisture 
content and water absorption capacity of ATBC patches is 
more or less the same as the DBP patch. As the amount of 
PVP increases, thickness as well as moisture content and 
water absorption capacity of the DBP and ATBC patches 
at different humidities increases. The hydrophilic nature of 
PVP has to be taken into account with regard to their higher 
moisture content and higher water absorption capacity.
In vitro drug release studies
Release of a drug from a transdermal drug delivery 
system mainly involves diffusion factors (Tojo et al., 1985). 
One such factor is the amount of hydrophilic polymer. As 
the amount of hydrophilic polymer (PVP) increases, disso-
lution of more and more PVP in the diffusion medium forms 
pores which increase the rate of diffusion. However, excess 
amounts of PVP will produce such a high viscosity that drug 
diffusion through the patch may be hampered. From Table 
III, it is clear that when the ratio of EC and PVP is 2:1 (F6) 
maximum release of glipizide occurs along with maximum 
release rate compared to the higher ratios present in F7 and 
F8. In the case of F5, where the ratio is lower (1.5:1), both 
the parameters reduce appreciably, probably due to the 
deposition of excess PVP in diffusion rivulets in the matrix 
patch. The patch F8 having the ratio 6:1 provided 27.4% 
cumulative release at 8 h whereas F7 (ratio 3:1) and F6 (2:1) 
yielded 42.81% cumulative release and 70.21% cumulative 
release at 8 h, respectively. Due to deposition of excess PVP 
in diffusion rivulets, F5 provided a lower percentage of 
cumulative release at 8 h (65.41%). The patches containing 
ATBC provided a lower percentage of drug release than 
the DBP patch. F9 and F10 yielded 46.58% cumulative 
release and 44.86% cumulative release, respectively. This 
is due to the fact that higher molecular weight ATBC was 
embedding between the polymeric chains and hampering 
drug release, although F9 and F10 patches had the same 
TABLE III - Release parameters of glipizide from various patches
Patch 
Code
Cumulative amount 
of release at 8 h 
(µg/cm2)
Release 
rate
(µg/cm2/h)
Cumulative amount 
of % release
at 8 h (%)
Best fit regression equation 
for release plot
r2
F5
F6
F7
F8
F9
F10
335 ± 24
410 ± 29
281 ± 18
160 ± 15
272
262
39.107
50.06
20.616
16.488
32.143
34.726
65.41
70.21
42.81
27.4
46.58
44.86
Q = 39.107 X + 17.143
Q = 50.06   X + 21.607
Q = 20.616 X - 13.766
Q = 16.488 X + 30.179
Q = 32.143 X + 17.357
Q = 34.726 X + 10.357
0.9928
0.9968
0.9789
0.9825
0.9821
0.9855
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ratio of EC and PVP and amount of plasticizer as patches 
F5 and F6, respectively. 
When the cumulative amount of drug released per 
unit area (µg/cm2) is plotted against time (h) in Figure 1, 
linear plots are obtained for all the patches. Therefore, the 
drug release from the patches followed zero-order kinetics. 
A linear relationship between % release and square root 
of time was found (Figure 2) as proposed by Higuchi’s 
theory, indicating the diffusion controlled mechanism of 
drug release.
CONCLUSIONS
DBP and ATBC were used as plasticizers. Plasticizers 
at a concentration of 20% and 30% of the total polymer 
weight were added. However, only 30% plasticizer patches 
were smooth and flexible whereas other patches were brit-
tle and not manageable. The patches prepared from DBP 
were smooth and flexible, providing greater drug release 
than ATBC patches. DBP was therefore selected as a better 
plasticizer than ATBC. PVP at different concentrations was 
used for the patch where greater amounts of PVP were asso-
ciated to higher drug release. However, 200 mg PVP in the 
F5 patch produced slightly lower release than the F6 patch. 
Considering all the factors such as original patch quality, 
quality of the patch piece after 8 h study, total cumulative % 
release after 8 h, uniformity in release rate at hourly intervals 
and release profile, whether following diffusion controlled 
mechanisms and Higuchi modeling or otherwise, the final 
polymer patches underwent further studies for permeation, 
pharmacokinetic studies using suitable animal models etc. 
The ideal patch was F6 but the F5 patch may also be consi-
dered for permeation etc.
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